Key statistics dashboard for PharmaCyte Biotech, Inc. (PMCB). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells.
Stock Data
| Price | $0.42 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.17 |
| Price / Book | 0.15 |
| P/S | 0.00 |
| P/FCF | -1.10 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 40.30 |
| Quick Ratio | 40.30 |
| Cash Ratio | 23.08 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -2.67 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.78 |
| Cash per share | 2.84 |
| FCF per share | -0.37 |
| Tangible Book Value per share | 2.78 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Related companies: BCLI · CYCN · IBO · KTTA · NBY · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of PMCB: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks